Published in Eur J Immunol on June 01, 1972
In vitro generation of tumor-specific cytotoxic lymphocytes. Secondary allogeneic mixed tumor lymphocyte culture of normal murine spleen cells. J Exp Med (1977) 3.11
Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48
Generation of T-helper cells in vitro. I. Cellular and antigen requirements. J Exp Med (1977) 1.07
The T cell-dependent period of the immune response to sheep erythrocytes. Immunology (1976) 0.82
Tolerance induction in B lymphocytes but thymus-dependent antigens. T cells may abrogate B-cell tolerance induction by prevent an antibody response. J Exp Med (1975) 0.80
Regulation of IgG antibody synthesis by a B cell component. Immunology (1977) 0.75
Characterization of dextran-activated T-cell factors. Immunology (1976) 0.75
The mechanism of interaction between T and B lymphocytes in the in vitro response to sheep erythrocytes. Non-specific collaboration across a dialysis membrane. Immunology (1975) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
A receptor for antibody on B lymphocytes. I. Method of detection and functional significance. J Exp Med (1972) 7.47
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet (1983) 5.64
The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. J Exp Med (1975) 5.48
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
A receptor for antibody on B lymphocytes. II. Immunochemical and electron microscopy characteristics. J Exp Med (1972) 4.63
Specific inactivation of thymus-derived (T) and non-thymus-derived (B) lymphocytes by 125I-labelled antigen. Nat New Biol (1971) 4.55
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Mechanism of eosinophilia. II. Role of the lymphocyte. J Exp Med (1970) 4.34
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature (1991) 4.04
The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med (1971) 4.03
Induction of self-tolerance in mature peripheral B lymphocytes. Nature (1989) 4.02
Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57
Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med (1983) 3.52
Mechanism of eosinophilia. I. Factors affecting the eosinophil response of rats to Trichinella spiralis. J Exp Med (1970) 3.40
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol (1985) 3.18
Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature (1985) 3.11
Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell (1993) 3.09
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
T cell-dependent suppression of an anti-hapten antibody response. Transplant Rev (1975) 3.06
Interaction between lymphocytes in immune responses. Cell Immunol (1971) 3.03
Separation of suppressor and killer T cells by surgace phenotype. Nature (1976) 3.03
HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature (1987) 2.96
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature (1975) 2.91
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control. J Exp Med (1980) 2.88
Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol (1996) 2.85
Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology (2005) 2.79
Cell-to-cell interaction in the immune response. X. T-cell-dependent suppression in tolerant mice. J Exp Med (1974) 2.77
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry (2006) 2.65
T-cell lines producing antigen-specific suppressor factor. Nature (1978) 2.63
Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48
Tolerance, enhancement and the regulation of interactions between T cells, B cells and macrophages. Transplant Rev (1972) 2.44
Modulation of cytokine production by transforming growth factor-beta. J Immunol (1989) 2.42
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Mycobacterium leprae antigens involved in human immune responses. I. Identification of four antigens by monoclonal antibodies. J Immunol (1985) 2.40
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science (1985) 2.27
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier cells. J Exp Med (1977) 2.22
Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. J Exp Med (1970) 2.17
Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med (1994) 2.15
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15
Tolerance of T-cell clones is associated with membrane antigen changes. Nature (1983) 2.10
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. Eur J Immunol (1976) 2.05
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev (1972) 2.02
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A (1998) 2.01
Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. Science (1991) 1.97
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med (1996) 1.96
Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol (1998) 1.96
Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. J Exp Med (1972) 1.96
Circulating T and B lymphocytes of the mouse. II. Lifespan. Cell Immunol (1973) 1.94
Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J Exp Med (1970) 1.93
Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Receptor for antibody-antigen complexes used to separate T cells from B cells. Nat New Biol (1972) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
Role of macrophages in in vitro induction of T-helper cells. Nature (1975) 1.84
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
B Cell heterogeneity - difference in the size of B lymphocytes responding to T dependent and T independent antigens. Cell Immunol (1975) 1.78
Immunoreactivity of a 70 kD protein purified from Mycobacterium bovis Bacillus Calmette-Guerin by monoclonal antibody affinity chromatography. J Exp Med (1986) 1.78
Cell interactions in the immune response in vitro. II. The requirement for macrophages in lymphoid cell collaboration. J Exp Med (1972) 1.77
Suppressor-cell induction in vitro. IV. Target of antigen-specific suppressor factor and its genetic relationships. J Exp Med (1978) 1.77
Synergy among thymocytes and peripheral lymph node cells in the in vitro generation of lymphocytes cytotoxic to alloantigens. Transplant Proc (1973) 1.76
Homology of the 70-kilodalton antigens from Mycobacterium leprae and Mycobacterium bovis with the Mycobacterium tuberculosis 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Infect Immun (1989) 1.75
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Monospecificity of bone marrow-derived lymphocytes. J Exp Med (1973) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol (1988) 1.69
Cell-mediated immune response in vitro. I. A new in vitro system for the generation of cell-mediated cytotoxic activity. Cell Immunol (1972) 1.67
Mechanisms for eosinophilic and neutrophilic leucocytoses. Br Med J (1971) 1.66
Suppressor cell induction in vitro. I. Kinetics of induction of antigen-specific suppressor cells. Eur J Immunol (1976) 1.65
Migrainous vertigo: prevalence and impact on quality of life. Neurology (2006) 1.64
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev (1995) 1.63
The role of macrophages in the generation of T-helper cells. I. The requirement for macrophages in helper cell induction and characteristics of the macrophage-T cell interaction. Cell Immunol (1975) 1.62
Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol (1994) 1.61
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
Relationship between Fc receptors, antigen-binding sites on T and B cells, and H-2 complex-associated determinants. J Exp Med (1975) 1.58
Role of macrophages in the generation of T helper cells. IV. Nature of genetically related factor derived from macrophages incubated with soluble antigens. Eur J Immunol (1976) 1.57
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol (1997) 1.54